Sono-Tek Corp. 10-Q Summary: Quarter Ended May 31, 2010
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended May 31, 2010 for Sono-Tek Corporation, a smaller reporting company. The company designs and manufactures ultrasonic atomizing nozzles and coating systems for electronics, medical devices, advanced energy, and industrial applications. International sales now represent approximately 60% of total revenues.
Key Financial Metrics
| Metric | Q1 2011 (Ended May 31, 2010) | Q1 2010 (Ended May 31, 2009) |
|---|---|---|
| Net Sales | $2,283,651 | $1,464,728 |
| Gross Profit | $1,117,028 | $657,381 |
| Gross Margin | 49% | 45% |
| Operating Income | $97,896 | ($170,561) |
| Net Income | $94,752 | ($169,427) |
| Diluted EPS | $0.01 | ($0.01) |
| Cash from Operations | $151,690 | $119,376 |
| Cash and Equivalents | $1,889,641 | $1,471,379 |
| Total Debt (Current + Long Term) | $362,528 | Filing does not provide total debt for prior period |
| Working Capital | $3,208,147 | Filing does not provide working capital for prior period |
| Current Ratio | 3.2:1 | 3.0:1 (as of Feb 28, 2010) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 56% ($819,000) year-over-year, driven by growth in fluxer units, EZ Flux units, Servo units, Solder Recovery Systems, and WideTrack units.
- Profitability Turnaround: The company returned to profitability with a net income of $94,752, compared to a net loss of $169,427 in the prior year. This was primarily due to higher sales volume and an improved gross margin mix.
- Margin Expansion: Gross profit margin improved from 45% to 49% due to a more profitable product mix.
- Expense Increases: Operating expenses rose $191,000. Research and development costs increased $39,000 due to added engineering personnel. Marketing and selling expenses increased $113,000 due to higher salaries, international commissions, and travel.
- Liquidity: Working capital increased by approximately $133,000. Cash provided by operating activities increased to $152,000 from $119,000.
Guidance, Outlook, and Risks
- Outlook: Management expects continued growth driven by international expansion and new markets in medical devices (stent coating), advanced energy (solar/fuel cells), and WideTrack coating systems. No specific numerical guidance was provided.
- Capital Resources: The company maintains a $500,000 revolving line of credit with $350,000 outstanding and $150,000 available. The line is collateralized by all company assets and requires an annual 30-day paydown.
- Risks: Forward-looking statements are subject to risks including general economic conditions, competition, timely product development, and the ability to enforce patents. The company notes that cash balances occasionally exceed FDIC insurance limits.
- Unusual Items: None reported. The filing notes no legal proceedings or defaults on senior securities.
Investor Verification Checklist
- Verify the sustainability of the 49% gross margin, which management attributes to a "more profitable mix of products."
- Confirm the status of the $350,000 line of credit and the company's ability to meet the annual 30-day paydown requirement.
- Assess the concentration risk of international sales, which now comprise approximately 60% of revenue.
- Review the inventory levels ($1.86M) relative to the recent sales growth to ensure no obsolescence issues.
- Monitor the impact of increased R&D and marketing spend on future operating leverage.